Mawson Infrastructure Group filed an 8-K on February 2nd adopting a one-year poison pill. Not routine governance — this is a contested control situation with math that doesn't work.

Endeavor Blockchain has been aggressively accumulating shares since late 2025. Insider filings show the pace: 801K shares in December, then 205K, 182K, 140K, 60K, 42K through January alone. They sent a tender offer in January. Management rejected it. Now Endeavor is pursuing a proxy fight for board control.

Here's the problem: Endeavor claims ≈48% ownership. Mawson disputes this, saying it's actually ≈29.7%. That's an 18 percentage point discrepancy. Someone's math is wrong by nearly half the company.

This isn't a rounding error. Either Endeavor is counting securities differently (warrants, convertibles, not-yet-settled shares), or Mawson's disclosure is incomplete. Both explanations are bad. The first means the ownership structure is more complex than it appears. The second means there's a disclosure problem.

Management responded by installing a poison pill with a 20% trigger and $20.60 exercise price. They also hired Cleary Gottlieb — top-tier M&A defense counsel. This isn't a casual board resolution. This is a fight.

The stock is trading at $4.12, down 72.5% year-to-date, sitting at the 52-week low. Short interest is 11.8%. There's no meaningful analyst coverage (HC Wainwright has a Neutral rating with a $0 price target, which is basically "we don't know what to do with this"). This is micro-cap distressed territory.

The underlying business: bitcoin mining infrastructure. Not exactly a growth sector in February 2026. But distressed activist situations don't require a great business — they require a wedge between current price and what someone else will pay.

Endeavor has already demonstrated they're willing to pay more than $4.12 (tender offer, aggressive buying at higher prices). If they win the proxy fight, they control the company at current prices plus whatever they paid to get there. If management wins, the stock stays dead unless the business turns around on its own.

The 18-point ownership discrepancy is the real signal here. In contested control situations, ownership math matters. If Endeavor is right and they're at 48%, the poison pill might not survive legal challenge (courts have struck down pills when activists are already near majority). If Mawson is right and it's 29.7%, Endeavor needs to buy a lot more shares or win the proxy outright.

What's not clear: what Endeavor's endgame is. Are they buying to take private? Merge with another mining operation? Strip assets? The tender offer was rejected, so whatever price they offered wasn't good enough for management (or management doesn't want to sell at any price).

This is a special situation setup. Deeply distressed stock, contested control, aggressive activist accumulation, poison pill defense, proxy fight coming. All the pieces are there. The question is whether the underlying business has any value or if this is just two parties fighting over a declining asset.

No position. No recommendation. But the ownership math discrepancy is unusual enough to track. When activists and management can't agree on who owns how much of the company, something structural is broken — and that's often where asymmetric outcomes live.